In addition to inhibitory and costimulatory receptors on T cells, various therapeutic combinations have been emerged which include pairing checkpoint inhibitors with (1) tumor vaccines; (2) IDO inhibitors; (3) oncolytic viruses; (4) inducers of immunogenic cell death; and (5) targeted therapy and various other therapies. This evidence concerns the gene IDO1 and neoplasm.